A Three-Part FTIH Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK3439171A, in a Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Dose Escalation Study and to Evaluate the Effect of Food on a Single Oral Dose of GSK3439171A in Healthy Adult Participants
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs GSK-3439171A (Primary)
- Indications Muscular dystrophies
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Sep 2019 Status changed from recruiting to completed.
- 28 Jun 2019 Planned number of patients changed from 150 to 75.
- 28 Jun 2019 Planned End Date changed from 30 Jun 2019 to 19 Aug 2019.